Protocol for Women at Increased Risk of Developing Breast Cancer

Phase 2 Completed 72 enrolled Carol Fabian, MD Susan G. Komen Breast Cancer Foundation · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.

Timeline

Start: 2003-04
Primary completion: 2009-12
Completion: 2009-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Celecoxib	Other / unclassified	400 mg	Oral

Protocol for Women at Increased Risk of Developing Breast Cancer

Summary

Timeline

Drugs

Indications